ACTION and the Academic Research Consortium (ARC) aimed to harmonize definitions of pediatric and CHD AEs for use in clinical trials, registries, and regulatory evaluation.
Purpose Cardiac disease results in significant morbidity and mortality in patients with muscular dystrophy (MD). Single centers have reported their ventricular assist device (VAD) experience in specific MDs and in
Despite the fact that VADs are now regarded as an important treatment option in pediatric heart failure, most hospitals perform less than 10 VAD surgeries in children a year. “ISHLT
ISHLT Consensus Statement for the Selection and Management of Pediatric and CHD on VAD Read More »
Right heart failure (RHF) after LVAD implantation can negatively impact a child’s transplant candidacy and survival. Successful LVAD outcomes require anticipation, prevention, early identification, and management of RHF, but there
Right Heart Failure Considerations in Pediatric VADs Read More »
IMPROVING STROKE OUTCOMES IN CHILDREN SUPPORTED WITH A VENTRICULAR ASSIST DEVICE IN A QUALITY IMPROVEMENT NETWORK ACTION has been working to reduce the frequency of stroke associated with pediatric VAD
ABCs of Stroke Prevention Read More »
A MULTICENTER REGISTRY ANALYSIS The HeartMate 3™ LVAD was originally designed for use in adults with heart failure. This study, published in the Journal of Heart and Lung Transplantation on
